| $15K |
| — |
| 0.170% |
| 0.00% |
| 3 | MONTAG A & ASSOCIATES INC | 3K | $4K | 0.0% | 0.044% | 0.00% |
| 4 | UBS Group AG | 517 | $662 | -69.4% | 0.007% | 0.00% |
| 5 | Pflug Koory, LLC | 333 | $426 | 0.0% | 0.005% | 0.00% |
| 6 | JONES FINANCIAL COMPANIES LLLP | 26 | $32 | 0.0% | 0.000% | 0.00% |
| 7 | SBI Securities Co., Ltd. | 20 | $26 | -98.1% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in SLXN — a direct measure of their conviction.
Institutions that fully closed their SLXN position in Q1 2026
No institutional exits this quarter.
| 0.16% |
| 0.05 pp |
| $0M |
| 53% |
| Q3 2024 | 6 | — | 0.21% | — | $1M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
1 institutions opened new positions in SLXN during Q1 2026, while 0 fully exited. 1 added to existing positions and 5 trimmed.
SLXN institutional ownership rose by 0.26 percentage points quarter-over-quarter, with a net change of +1 holders.
The top 10 institutions account for 100.0% of all reported 13F value in SLXN, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Silexion Therapeutics Ltd. (SLXN) Institutional Ownership